Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 3, 2010, Pages 858-865

  Jin, Cheng Hao ^a   Chae, Su Young ^a   Kim, Tae Hyung ^a   Yang, Han Kwang ^b   Lee, Eun Young ^b   Song, Yeong Wook ^b   Jo, Dong Gyu ^a   Lee, Kang Choon ^a  

^a Sungkyunkwan University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE EROSION; CARTILAGE DEGENERATION; CELL INFILTRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; EDEMA; ERYTHEMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL;

ANIMALS; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CYTOKINES; HUMANS; IMMUNITY, HUMORAL; JOINTS; JURKAT CELLS; LYMPHOCYTES; MALE; MICE; MICE, INBRED DBA; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77249126595     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.159517     Document Type: Article

References (35)

1. Ashkenazi A and Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305-1308.
2. Ashkenazi A and Dixit VM (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260.
3. Borchers AT, Keen CL, Cheema GS, and Gershwin ME (2004) The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum 34:465-483.
4. Brand DD, Kang AH, and Rosloniec EF (2003) Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 25:3-18.
5. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, and Catalano M (1996) Doserange and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 39:1092-1101.
6. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, and Hood L (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADDdependent apoptosis and activate the NF-κB pathway. Immunity 7:821-830.
7. Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326:1-16.
8. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, et al. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363- 14367.
9. Evans CH (2004) On the TRAIL of an arthritis cure. Gene Ther 11:735-736.
10. Feldmann M, Brennan FM, and Maini RN (1996) Rheumatoid arthritis. Cell 85:307-310.
11. Firestein GS and Zvaifler NJ (1990) How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 33:768-773.
12. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, et al. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443-1450.
13. Griffith TS and Lynch DH (1998) TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10:559-563.
14. Gura T (1997) How TRAIL kills cancer cells, but not normal cells. Science 277:768.
15. Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322:1277-1289.
16. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, and Chen YH (2003) Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 4:255-260.
17. Li EK, Tam LS, and Tomlinson B (2004) Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 26:447-459.
18. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, and Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602.
19. Liu Z, Xu X, Hsu HC, Tousson A, Yang PA, Wu Q, Liu C, Yu S, Zhang HG, and Mountz JD (2003) CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 112:1332-1341.
20. Luross JA and Williams NA (2001) The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 103:407-416.
21. Lünemann JD, Waiczies S, Ehrlich S, Wendling U, Seeger B, Kamradt T, and Zipp F (2002) Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 168:4881-4888.
22. Mackay F and Kalled SL (2002) TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 14:783-790.
23. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, et al. (1997) A novel receptor for Apo2L/ TRAIL contains a truncated death domain. Curr Biol 7:1003-1006.
24. Martínez-Lorenzo MJ, Anel A, Saez-Gutierrez B, Royo-Cañas M, Bosque A, Alava MA, Piñeiro A, Lasierra P, Asín-Ungría J, and Larrad L (2007) Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin Immunol 122:28-40.
25. Pan G, Ni J, Wei YF, Yu G, Gentz R, and Dixit VM (1997a) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818.
26. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, and Dixit VM (1997b) The receptor for the cytotoxic ligand TRAIL. Science 276:111-113.
27. Panayi GS, Lanchbury JS, and Kingsley GH (1992) The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 35:729-735.
28. Schnabel A and Gross WL (1994) Low-dose methotrexate in rheumatic diseases-efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 23:310-327.
29. Smolen JS, Tohidast-Akrad M, Gal A, Kunaver M, Eberl G, Zenz P, Falus A, and Steiner G (1996) The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol 25:1-4.
30. Song K, Chen Y, Göke R, Wilmen A, Seidel C, Göke A, Hilliard B, and Chen Y (2000) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 191:1095-1104.
31. Tsokos GC and Tsokos M (2003) The TRAIL to arthritis. J Clin Invest 112:1315-1317.
32. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, and Smith CA (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682.
33. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386-5397.
34. Yao Q, Seol DW, Mi Z, and Robbins PD (2006) Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res Ther 8:R16.
35. Youn YS, Shin MJ, Chae SY, Jin CH, Kim TH, and Lee KC (2007) Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biotechnol Lett 29:713-721.